S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ITOS iTeos Therapeutics Inc

7.34

0.02 (0.27%)

Last Updated: 12:52:05

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more iTeos Therapeutics Charts.

iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more iTeos Therapeutics Charts.

iTeos Therapeutics Inc News

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday 12 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (3 weeks ago) • Edgar (US Regulatory)

iTeos to Participate in Upcoming Investor Conferences
Tuesday 26 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 12 November 2024 (2 months ago) • Edgar (US Regulatory)

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Tuesday 12 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 4 November 2024 (2 months ago) • Edgar (US Regulatory)

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
Thursday 24 October 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Monday 21 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 16 September 2024 (3 months ago) • Edgar (US Regulatory)

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
Saturday 14 September 2024 (4 months ago) • GlobeNewswire Inc.

More iTeos Therapeutics Inc News Articles

Global Developments (PK)

Asia Broadband (PK)

Digital Brand Media and ... (PK)

Kraig Biocraft Laborator... (QB)

Hallmark Venture (PK)

Bioelectronics (PK)

Elite Pharmaceuticals (QB)

Code Green Apparel (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions